Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T16:38:02.329Z.
Calculation as of: 2026-10-06T16:38:02.329Z.
Quote observation: 2026-10-06T16:34:43.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 47811cd6fce140e68777d2609bf88a35ade871fb75fdb0cf4ca3c33c868081b2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Medicus Pharma Ltd. Common Stock
Market Cap
$10.06M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$10.38M
Price/OCF Ratio
N/A
TTM Avg
5.31
3Y Avg
5.31
5Y Avg
5.31
Market Cap
$10.52M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$9.57M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medicus Pharma Ltd. Common Stock (MDCX) | $10.06M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $9.92M | N/A | N/A | N/A | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.36M | N/A | N/A | N/A | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.38M | N/A | 5.31 | 5.31 | 5.31 |
| Ainos, Inc. (AIMD)vs › | $9.72M | N/A | N/A | N/A | N/A |
| MetaVia Inc. (MTVA)vs › | $9.68M | N/A | N/A | N/A | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.52M | N/A | N/A | N/A | N/A |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.57M | N/A | N/A | N/A | N/A |
| Senti Biosciences, Inc. (SNTI)vs › | $10.31M | N/A | N/A | N/A | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.70M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
